Kymera Therapeutics (KYMR) Stock Gets Fair Value Bump After KT 621 Timeline Shift

Yahoo Finance ·

Kymera Therapeutics (KYMR) Stock Gets Fair Value Bump After KT 621 Timeline Shift Bailey Pemberton Fri, July 3, 2026 at 2:12 AM EDT 3 min read KYMR Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Kymera Therapeutics now carries an updated fair value estimate of US$123.76, a modest step up from US$119.19 that has drawn attention to how analysts are fine tuning their price targets. Much of the recent commentary links these changes to earlier than expected completion of the BROADEN2 trial, a pulled forward KT-621 readout, and fresh views on how much of that opportunity belongs in Kymera Therapeutics' valuation today. As you read on, you will see how these moving pieces fit together and what to watch as the story develops from here. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Kymera Therapeutics. Several firms, including B. Riley, Truist, Canaccord, and BofA, have lifted Kymera Therapeutics price targets, with revisions such as B. Riley moving from US$117 to US$155 and BofA from US$110 to US$125. These changes reflect updated views on KT-621 and its role in the valuation. Completion of the BROADEN and BROADEN2 phase 2b enrollment for KT-621 in atopic dermatitis around six months ahead of earlier company timing has led B. Riley, Canaccord, and BofA to bring forward their expectations for key data and launch timing. Truist highlights clinician and key opinion leader interest in an oral atopic dermatitis therapy with efficacy that could be comparable to established biologics. The firm views this as supportive for Kymera Therapeutics opportunity set in this indication. Canaccord points to the AbbVie and Apogee Therapeutics deal as supportive for inflammation and immunology companies, explicitly citing Kymera Therapeutics as a potential beneficiary of increased sector attention. BofA models US$6b in nominal peak sales for KT-621 in atopic dermatitis. This helps explain the firm's higher Kymera Therapeutics target price and focus on this single asset as a central value driver. Street commentary in the provided research is skewed toward the upside, so potential concerns such as execution risk around KT-621 trials, regulatory outcomes, and commercial uptake are not fully detailed in these reports and remain key watchpoints for Kymera Therapeutics investors. Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives! We've flagged 4 risks for Kymera Therapeutics. See which could impact your investment. The fair value estimate for Kymera Therapeutics has increased from US$119.19 to US$123.76. The long-term revenue growth assumption has shifted from a 7.35% decline to a 4.61% decline. The assumed net profit margin is largely unchanged, easing from 18.98% to 18.92%. The implied future P/E multiple remains very large, moving from about 1,885.69x to 1,804.72x. The discount rate has adjusted slightly from 7.13% to 7.22%. Narratives connect Kymera Therapeutics' scientific and commercial story to a forward looking financial framework so you can see how clinical milestones, partnerships and spending plans line up with fair value estimates. They update over time as new trial data, deals and guidance come through. Head over to the Simply Wall St Community and follow the Narrative on Kymera Therapeutics to stay up to date on: How advancing STAT6, TYK2 and other immunology programs, including planned Phase II and III trials targeting biologics like efficacy in an oral form, could open up new treatment markets. The role of partnerships such as Sanofi on the IRAK4 program and Gilead on KT-200, plus the plan to file at least one new IND per year, in expanding Kymera Therapeutics' pipeline and potential revenue sources. Key risks around high R&D spending, increasing competition in areas like STAT6, dependence on partners to progress trials and the need to manage cash resources beyond the current runway into mid 2027. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KYMR . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

DYAX Investor Sentiment

Bullish (Long) 42% · Bearish (Short) 58%

514 participants

Related News

원문 보기 — Yahoo Finance